Table 2 Pathway analyses of conserved protein and transcript alterations in HLRCC versus Non-Syndromic (NS) ULMs.

From: Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patients

Diseases or Biofunctions

Activation z-score

Cell proliferation of tumor cell lines

3.699

Abdominal neoplasm

2.642

Glycolysis of cells

2.567

Growth of tumor

2.52

Cell proliferation of sarcoma cell lines

2.338

Migration of cells

−1.98

Cell spreading of tumor cell lines

−2.019

Shape change of tumor cell lines

−2.222

Cytostasis

−2.237

Quantity of reactive oxygen species

−2.318

  1. Table denotes top 5 functional pathways predicted to be activated (positive z-score) or inhibited (negative z-score) in HLRCC vs NS ULMs (Ingenuity pathway analyses, p-value < 0.05).
Back to article page